With the original SBIR Phase I award made to the firm in California, the two key players on the management team - to include the ceo and PI - were professionally engaged in Cambridge MA. By the time of awarding of Phase II, efforts had moved to Cambridge. Travera is using a breakthrough technology to measure which cancer drugs work against each individualâs unique cancer cells. The focus is on developing a universal biomarker for enabling oncologists quickly to determine which drugs to prescribe based on the actual responses of their patientsâ tumor cells to candidate drugs. The companyâs initial test is based on this technology; a new measurement tool called the Suspended Microchannel Resonator (SMR) capable of enabling exquisitely precise measurements of the effects of cancer drugs on cancer c
